TAO Synergies TAOX
NASDAQ TAOX
$4.14 +0.13 (+3.24%)
As of: Sep 9, 2026 · 11:58 AM EDT

TAO Synergies (TAOX) Cash from Financing Activities (2020 - 2026)

TAO Synergies' (TAOX) quarterly Cash from Financing Activities came in at -$402371.0 in Q2 2026, down 108.41% on a YoY basis from $4.8 million in Q2 2025, and down 138.08% quarter-over-quarter from -$169006.0 in Q1 2026.

Analysis

TAO Synergies (TAOX) Cash from Financing Activities (2020 - 2026) Analysis & Trends

TAO Synergies (TAOX) has reported Cash from Financing Activities for 7 consecutive years, with -$402371.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Cash from Financing Activities fell 108.41% year-over-year to -$402371.0; the trailing twelve-month figure through Jun 2026 stood at $18.6 million (up 488.24% YoY), and the FY2025 full-year result was $23.1 million, up 551.67% from the prior year.
  • Cash from Financing Activities eased to -$402371.0 in Q2 2026 per TAOX's latest filing, from -$169006.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $17.8 million in Q4 2025 and bottomed at -$822362.0 in Q1 2025.
  • Historically, Cash from Financing Activities has averaged $3.3 million across 5 years, with a median of $49.0 in 2023.
  • The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 1571849.02% in 2024, then jumped 2323.73% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $13.9 million in 2022, then plunged by 100.0% to -$51.0 in 2023, then tumbled by 1571849.02% to -$801694.0 in 2024, then surged by 2323.73% to $17.8 million in 2025, then sank by 102.26% to -$402371.0 in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered -$402371.0, -$169006.0, and $17.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Amgen 211.88 Bn 197.89 Bn 7.24 Bn -1.48 Bn
2 Gilead Sciences 181.55 Bn 178.37 Bn 6.22 Bn 2.34 Bn
3 Vertex Pharmaceuticals 132.31 Bn 124.45 Bn 2.84 Bn -426.70 Mn
4 Regeneron Pharmaceuticals 82.51 Bn 74.52 Bn 3.93 Bn -1.22 Bn
5 Argenx Se 61.54 Bn 56.36 Bn 1.37 Bn -
6 Moderna 54.69 Bn 49.55 Bn 52.00 Mn 14.00 Mn
7 Alnylam Pharmaceuticals 34.07 Bn 30.76 Bn 992.69 Mn 36.24 Mn
8 Biogen 31.41 Bn 30.12 Bn 1.96 Bn 1.30 Bn
9 Roivant Sciences 30.10 Bn 30.10 Bn 1.16 Mn -181.51 Mn
10 TAO Synergies 30.93 Mn 30.93 Mn - -402,371.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -402,371.00
Mar 31, 2026 -169,006.00
Dec 31, 2025 17.83 Mn
Sep 30, 2025 1.34 Mn
Jun 30, 2025 4.79 Mn
Mar 31, 2025 -822,362.00
Dec 31, 2024 -801,694.00
Dec 31, 2023 -51.00
Sep 30, 2023 49.00
Dec 31, 2022 13.93 Mn
Mar 31, 2022 553,150.00
Dec 31, 2021 4.97 Mn
Sep 30, 2021 672,795.00
Jun 30, 2021 18.85 Mn
Mar 31, 2021 12.64 Mn
Dec 31, 2020 -20.00 Mn
Mar 31, 2020 16.52 Mn